These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 26918675

  • 1. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
    Cao L, Li D, Feng P, Li L, Xue GF, Li G, Hölscher C.
    Neuroreport; 2016 Apr 13; 27(6):384-91. PubMed ID: 26918675
    [Abstract] [Full Text] [Related]

  • 2. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, Li G, Hölscher C.
    Brain Res; 2016 Mar 01; 1634():1-11. PubMed ID: 26453833
    [Abstract] [Full Text] [Related]

  • 3. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, Hölscher C.
    Neuropharmacology; 2018 May 01; 133():385-394. PubMed ID: 29462693
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN, Calió ML, Hölscher C, Pacheco-Soares C, Porcionatto M, Lobo AO.
    Neuropharmacology; 2020 Jan 01; 162():107813. PubMed ID: 31628935
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
    Zhang Z, Hao L, Shi M, Yu Z, Shao S, Yuan Y, Zhang Z, Hölscher C.
    J Parkinsons Dis; 2021 Jan 01; 11(2):529-543. PubMed ID: 33523018
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
    Shi L, Zhang Z, Li L, Hölscher C.
    Behav Brain Res; 2017 Jun 01; 327():65-74. PubMed ID: 28342971
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
    Ji C, Xue GF, Li G, Li D, Hölscher C.
    Rev Neurosci; 2016 Jan 01; 27(1):61-70. PubMed ID: 26351802
    [Abstract] [Full Text] [Related]

  • 20. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
    Zhang L, Zhang L, Li L, Hölscher C.
    J Parkinsons Dis; 2019 Jan 01; 9(1):157-171. PubMed ID: 30741689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.